GlassScriptPhysician profile
Richard D Guynes
NPI 1770526568
$26,219.79
in general payments reported to CMS, 2019-2025
44 companies · $3,171 in 2025
The $3,171 reported for 2025 was more than what 76% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,264 · 2021: $1,978 · 2022: $2,442 · 2023: $2,036 · 2024: $2,483 · 2025: $3,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,690.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $5,904.59 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $4,457.80 | 2019-2020 | |
| Edwards Lifesciences Corporation | $3,935.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $2,234.58 | 2019-2025 | |
| Boston Scientific Corporation | $1,880.48 | 2020-2025 | Watchman Access System, Avvigo Guidance System, Rotapro |
| Astrazeneca Pharmaceuticals LP | $1,314.49 | 2020-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $811.66 | 2021-2025 | Verquvo, Capvaxive |
| Philips North America LLC | $764.81 | 2019-2025 | (6571) Eagle Eye, (Am5) Lead Management, Lm Undivided |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.54 | 2019-2025 | Jardiance |
| Amgen INC. | $570.23 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $531.80 | 2019-2024 | Xarelto |
| Shockwave Medical, INC | $480.56 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $366.49 | 2019-2025 | Jot Dx, Diamondback Coronary, Coroflow |
| Pfizer INC. | $351.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $351.85 | 2019-2025 | Camzyos, Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Guynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.